LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiarie...
LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development
SHENZHEN, China, April 2, 2024 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiarie...
LifeTech Scientific Corporation (1302.HK) Announces 2023 Interim Results
SHENZHEN, China, Aug. 30, 2023 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated ...
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results. ...
FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US
SHENZHEN, China, Sept. 5, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtai...
LifeTech Scientific Corporation (1302.HK) Announces 2022 Interim Results
* Revenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items SHENZHEN, China, Aug. 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally ...
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
LifeTech and Medtronic Further Strategic Collaboration to Open New Chapter of Domestically-Made MRI-Conditional Pacemakers
SHENZHEN, China, Dec. 16, 2021 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 01302.HK) announced that it has extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone™ domestic pacemaker project" and to start the collaboration on domestically-mad...
LifeTech Scientific Corporation Announces 2021 Interim Results
SHENZHEN, China, Aug. 31, 2021 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 01302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 interim results. Compared with...
LifeTech announced the launch of its global post-market surveillance study for LAmbre (TM) LAA Closure System
FRANKFURT, Germany, July 3, 2017 /PRNewswire/ -- On June 30, at the Congenital and Structural Intervention Congress (CSI) 2017 inFrankfurt, LifeTech Scientific Corporation (Stock Code: 1302.HK) announced the launch of a 3-year global post-market surveillance (PMS) study for the LAmbreTM Left Atri...
LifeTech Announces CE Mark for LAmbre(TM) LAA Closure System
LONDON, June 16, 2016 /PRNewswire/ -- LifeTech (1302.HK) received CE Mark approval for its LAmbreTM left atrial appendage (LAA) closure system on 15 June 2016. This is the first CE marked LAA closure system fromChina. LAA closure is considered as an alternative to anticoagulation in atrial fibri...
